Cambridge, UK – 26 September 2016 - Cambridge based Inotec AMD Limited is pleased to announce the appointment of Chad Bateman as its new Chief Executive Officer on 1 October 2016.
Inotec AMD is a maker of mobile medical devices designed to heal chronic, hypoxic wounds that afflict millions of sufferers around the world every year. The global wound-care market is projected to grow to $18.3 billion globally in 2019, driven in part by changing life styles and ageing populations in many countries. There are some 400 million diabetes sufferers around the world, some 60 million of whom are likely to develop a lower limb ulcer. As more than 90% of wounds suffer from a lack of oxygen, the launch of NATROX™ addresses this serious concern with a simple, cost-effective application which treats a broad spectrum of chronic health problems.
Chad Bateman brings on board a proven track record of driving profitable revenue growth. Most recently, he was Vice President & General Manager - Europe and a member of the extended global leadership team of Acelity, a global leader in wound care and regenerative medicine. Chad has more than twenty years’ experience in sales and marketing, working in organisations such as Olympus and CR Bard Inc., the last seven years of which have been in senior executive positions within the wound care industry where he is highly regarded in the sector.
Dr Adrian Parton MBE, Chairman of Inotec AMD said “The Board of Directors are pleased to announce the appointment of Chad Bateman who will be starting his new role as CEO of the company in October and we believe that his extensive experience of the wound care market will help the Company drive the growth of Inotec AMD’s novel oxygen therapy products on a global basis”.
Mr Bateman commented that "I feel privileged to be joining Inotec AMD at such an exciting time for the organisation. The ever changing global health and care environment offers exceptional opportunities for new and innovative technologies, like Natrox™, to positively impact on existing patient pathways and outcomes. I feel particularly passionate about finding unique ways to help patients to heal quickly, improving quality of life; whilst reducing the capacity burden on health economies. My aim is for Inotec AMD to be a valued partner in our evolving wound care environment. It is time to make a difference."
Since raising its Series A round led by VC fund Amadeus Capital Partners, in April 2016, Inotec AMD has strengthened its sales teams across a number of key territories and has appointed Shona Macdonald as Business Director for UK and Ireland. Ms Macdonald has many years of experience in the wound care market, having most recently been Business Director – UK & Ireland at Molnlycke.Editor's Details
Last updated on: 27/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.